underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the... treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra...
Lugar:
Massachusetts | 22/11/2025 02:11:07 AM | Salario: S/. $179000 - 219000 per year | Empresa:
Madrigal underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the... treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra...
Lugar:
Waltham, MA | 04/12/2025 18:12:11 PM | Salario: S/. $177000 - 217000 per year | Empresa:
MadrigalGroup Senior Software Product Manager to lead the development, and delivery of innovative software products.... We are looking for someone with a tech-first mindset and experience leveraging generative AI in solving business challenges. What You'll Do At Omnidian...
underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the... treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra...
Lugar:
Florida | 14/11/2025 01:11:21 AM | Salario: S/. $176400 - 215600 per year | Empresa:
Madrigal underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the... treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra...
Lugar:
Florida | 08/11/2025 03:11:41 AM | Salario: S/. $176400 - 215600 per year | Empresa:
Madrigal, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first... to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c...
Lugar:
West Virginia | 04/11/2025 19:11:05 PM | Salario: S/. $176400 - 215600 per year | Empresa:
Madrigal, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first... to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c...
Lugar:
Michigan | 31/10/2025 18:10:40 PM | Salario: S/. $176400 - 215600 per year | Empresa:
Madrigal or zero deductible options and low out of pocket maximums People come first at McKinstry, and we go beyond the basic... information is based on market location. The McKinstry group of companies are equal opportunity employers. We are committed...
Lugar:
Spokane, WA | 05/12/2025 23:12:48 PM | Salario: S/. $134730 - 215550 per year
come first at McKinstry, and we go beyond the basic benefits with: Family formation benefits, including adoption and IVF..., dependent on the position offered. Base pay information is based on market location. The McKinstry group of companies are equal...
Lugar:
Seattle, WA | 22/11/2025 02:11:18 AM | Salario: S/. $123570 - 214100 per year
/ adaptation of RBC’s AI risk management framework and governance processes across the first and second line at City National Bank... of the Group Risk Management (GRM) AI initiative strategy to deliver efficiencies in GRM operational processes. Identify...